Hepatitis C virus kinetics in chimeric mice during antiviral therapy
Harel Dahari, Alan S. Perelson – 28 November 2007
A high‐fat diet and regulatory T cells influence susceptibility to endotoxin‐induced liver injury
Xiong Ma, Jing Hua, Abdiaziz R. Mohamood, Abdel Rahmin A. Hamad, Rajani Ravi, Zhiping Li – 29 October 2007 – In nonalcoholic fatty liver disease, the pathogenesis of progression from simple steatosis to steatohepatitis has not been fully clarified. Many factors, including oxidative stress and hepatic immune regulation, contribute to the inflammation in steatosis. Because regulatory T cells (Tregs) are important components of immune regulation, we have now investigated their role in the pathogenesis of nonalcoholic steatohepatitis.
Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy
Marco Binder, Georg Kochs, Ralf Bartenschlager, Volker Lohmann – 29 October 2007 – Hepatitis C virus (HCV) has been known to replicate with extremely varying efficiencies in different host cells, even within different populations of a single human hepatoma cell line, termed Huh‐7. Several reports have implicated the retinoic‐acid inducible gene I (RIG‐I)/ interferon regulatory factor 3 (IRF‐3) pathway of the innate antiviral response with differences in host cell permissiveness to HCV.
Reply:
Jean‐Baptiste Nousbaum, Jean‐François Cadranel, Club Francophone pour l'Etude de l'Hypertension Portale and l'Association Nationale des Hépato‐Gastroentérologues des Hôpitaux Généraux de France – 29 October 2007
Lower cutoff values for dipsticks may improve their accuracy in rapid diagnosis of spontanous bacterial peritonitis
Antonio de Barros Lopes, Alexandre Araujo, Mario Reis Alvares‐da Silva – 29 October 2007
Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial
James H. Lewis, Mary Ellen Mortensen, Steven Zweig, Mary Jean Fusco, Jeffrey R. Medoff, Rene Belder, Pravastatin in Chronic Liver Disease Study Investigators – 29 October 2007 – The hepatotoxic potential of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors in patients with underlying chronic liver disease remains controversial.
N‐glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus
Xue‐En Liu, Liesbeth Desmyter, Chun‐Fang Gao, Wouter Laroy, Sylviane Dewaele, Valerie Vanhooren, Ling Wang, Hui Zhuang, Nico Callewaert, Claude Libert, Roland Contreras, Cuiying Chen – 29 October 2007 – We evaluated the use of blood serum N‐glycan fingerprinting as a tool for the diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis induced by hepatitis B virus (HBV). A group of 450 HBV‐infected patients with liver fibrosis or cirrhosis with or without HCC were studied.
Changes in bile acid synthesis in gallstone disease: Cause, consequence, or neither?
- Read more about Changes in bile acid synthesis in gallstone disease: Cause, consequence, or neither?
Marco Bertolotti, Chiara Gabbi, Claudia Anzivino, Lucia Carulli, Nicola Carulli – 29 October 2007
Reply:
Winnie Yeo, Frankie K. F. Mo – 29 October 2007
The role of serpinb9/serine protease inhibitor 6 in preventing granzyme B–dependent hepatotoxicity
Heather W. Stout‐Delgado, Yonas Getachew, Thomas E. Rogers, Bonnie C. Miller, Dwain L. Thiele – 29 October 2007 – Virally infected hepatocytes are resistant to cytotoxic lymphocyte killing by perforin‐dependent and granzyme‐dependent effector mechanisms. The present studies were designed to examine the role of serine protease inhibitor 6 (SPI‐6) in limiting granzyme B–dependent cytotoxic effector mechanisms in the liver.